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PMS52
Validation of the CoMPlianCe-QueStionnaire-rheuMatology, a 
BehaVior-foCuSed PrediCtiVe adherenCe QueStionnaire, With the 
MoriSky MediCation adherenCe SCale
Pedersini R.1, Goren A.2, Ingham M.3
1Kantar Health, Epsom, UK, 2Kantar Health, New York, NY, USA, 3Janssen Scientific Affairs, LLC, 
Horsham, PA, USA
Objectives: Establish the Compliance Questionnaire Rheumatology (CQR) poten-
tial value as a predictive adherence tool by identifying similarities, differences 
and overall relationship between the CQR and the Morisky Medication Adherence 
Scale (MMAS-4). MethOds: Patients residing in the United States completed a self-
administered, Internet-based questionnaire in the fall of 2011. Patients self-reported 
a diagnosis of rheumatoid arthritis (RA). The cross sectional survey included the 
CQR, MMAS-4 and extensive treatment and demographic patient level data. CQR 
predicts patients that are likely to be adherent at 50%, 60%, 75%, 80%, 85%, 90% or 
95% levels. The MMAS-4 is scored from 0-4, with zero equal to perfect adherence. 
Frequency distributions were compared. Linear models looked at: inter-item cor-
relations, CQR score thresholds optimally differentiating adherent vs. non-adherent 
on MMAS-4, and ordinary least squares (OLS) analysis of the ability of the CQR to 
predict MMAS-4 scores. Results: Survey respondents were 76.2% female, 86.2% 
Caucasian, with mean age 56.4 years. Frequency distributions of the CQR and 
MMAS-4 were similar. The CQR provided much more detail at high adherence levels, 
and hence appears more discriminative in these patients. Comparing dichotomous 
adherent/non-adherent results, the optimal CQR threshold for predicting “adher-
ent patients” from MMAS-4, was 60%. Correlation between MMAS-4 and CQR was 
0.40. CQR scores can predict MMAS-4 scores, although the relationship appears 
weak. cOnclusiOns: Compared with MMAS-4, the CQR scale appears to be more 
sensitive at high levels of adherence. The CQR appears to be useful as a predictive 
tool. It does not require claims-based data to assess historical non-adherence, and 
so may be a useful alternative. These results warrant further exploration of the 
CQR as a way to stream rheumatology patients into appropriate treatment, based 
on their potential to be non-adherent.
PMS53
the CoSt of nonCoMPlianCe With alendronate SodiuM in the 
treatMent of oSteoPoroSiS in PoStMenoPauSal in Brazil
Ferre F., Brandão C.M.R
Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
Objectives: The aim of this study is to assess adherence among patients attended 
by the Secretary of State for Health of Minas Gerais (SES / MG) between 2008 and 2010 
with a diagnosis of osteoporosis and describe the cost of non-adherence to treat-
ment. MethOds: A retrospective cohort study from a database for administrative 
purposes of the SES / MG was made. Selected patients with a diagnosis of osteoporo-
sis in postmenopausal, with at least three records of dispensing drugs and age equal 
to or greater than 40 years. We calculated adherence to treatment considering the 
range of dispensing drugs. Then we proceeded to calculate the cost of non-adher-
ence from demographics and cost in Minas Gerais, Brazil. Results: 3905 patients 
were taking alendronate sodium distributed by Unified Health System Adherence 
to treatment of osteoporosis in Minas Gerais was 80 % and 20 % of irregular adher-
ence. Non-adherence to treatment increases by 20,4% the total cost of osteoporosis, 
considering pharmacological treatment and hospital treatment. cOnclusiOns: 
Adherence to treatment is an important component of treatment effectiveness. 
Poor adherence is related to high treatment costs and high incidence of osteoporo-
tic fractures. The use of administrative databases allows the evaluation of health 
programs, especially programs for dispensing medicines. Measures that increase 
adherence to drug treatment should be taken to reduce the costs and improve the 
effectiveness of osteoporosis treatment.
PMS54
froM the MiniMuM CliniCally iMPortant differenCe to the MiniMuM 
CoSt effeCtiVe differenCe for eQ-5d in PatientS With ChroniC 
WideSPread Pain
Coretti S.1, Ruggeri M.1, McNamee P.2
1Università Cattolica del Sacro Cuore, Rome, Italy, 2University of Aberdeen, Aberddeen, UK
Objectives: i) estimate the MCID for EQ-5D in patients with chronic widespread 
pain; ii) estimate the MECD for patients undergoing cognitive behavior therapy 
(CBT), prescribed exercise therapy (EX), and combination therapy, i.e. cognitive 
behavior therapy and prescribed exercise together (COMB). MethOds: Using data 
from a multi-center RCT, MCID was estimated through regression analysis and ROC 
curves. Moreover, average change, minimum detectable change and change dif-
ference approaches were applied. The minimum cost-effective difference (MCED) 
for the three patients’ subgroups allocated to each of the active treatments of the 
trial was estimated through ROC curve approach and through regression analysis. 
The MCED was computed using a threshold of £20,000-£30,000 per QALY as cost-
effectiveness anchor. Ordinary least squares was used in regression analysis while 
ROC were estimated based on logistic analysis Results: Estimates of MCID range 
between .05 and .33. Adopting a cost-effectiveness threshold of £20,000/QALY, 
the MCED was equal to .226, .062 and .104, for CBT, EX and COMB respectively. 
Adopting a cost-effectiveness threshold of £30,000/QALY, the MCED equaled .315, 
.067 and .119, for CBT, EX and COMB, respectively. However, estimates were sensi-
tive to the choice of the anchor and the estimation method. cOnclusiOns: The 
minimal important difference (MID) represents the smallest amount of benefit 
that the patient can recognize and value. It is useful in the design of clinical trials 
for sample size calculations and in the interpretation of results. However, it does 
not help in the allocation of health care resources. Minimum cost-effective dif-
ference (MCED) can be used to bridge MCID and cost-effectiveness, being defined 
as the smallest improvement in the HR-Qol instrument associated with a cost-
effective outcome. MCED allows understanding whether the minimum change 
perceived as meaningful is cost-effective, given a certain acceptability threshold. 
Objectives: This study reports real-world utilization patterns observed for rheuma-
toid arthritis (RA), psoriatic arthritis (PSA), and ankylosing spondylitis (AS) patients 
treated with golimumab (GLM). MethOds: Patients with an ICD-9 code for RA, PSA, 
or AS receiving ≥ 2 fills of GLM as their first biologic medication (bionaive) or most 
recent biologic medication (bio-experienced) were identified between 1/1/2008 and 
12/31/2010 in a large health care claims dataset (Truven Health). Patient characteris-
tics and refill patterns were summarized using descriptive statistics .The proportion 
of adherent refills was calculated as the number of refills occurring between 21and 
38 days from a previous fill divided by the total refill intervals. Results: A total of 
1,515 patients with ≥ 2 GLM fills and a diagnosis of RA (n= 1,036), PSA (n= 325) or AS 
(n= 154) were identified in the database. Median age was: RA 52 years; PsA 50 years; 
AS 47 years. The majority were bio-experienced (RA 72%; PsA 79%; AS 79%). A total 
of 13,738 GLM refills were observed (RA 9,398; PsA 2,961; AS 1,369). The number of 
refills per patient ranged from 2 to 34 with a mean (SD) of 10.1 (7.25) and median 
of 8. The mean (SD) interval for all refills was 34.8±13.0 days; median was 31 days. 
Median refill interval for RA, PsA and AS was 31 days in bio-experienced subgroups 
and 32 days for bionaive subgroups. The proportion of adherent refills overall was 
78%; (RA 79%; PSA 76%; AS 78%). The proportion of adherent refills appeared similar 
for bionaive and bioexperienced patients except in the AS group (bionaive 73.8%; 
bioexperienced 79.3%). cOnclusiOns: This retrospective observational study con-
firms earlier findings that GLM is utilized largely in patients who have used other 
biologic medications. A high proportion of GLM-treated patients were adherent to 
refilling medication and median refill intervals occurred as recommended in the 
GLM prescribing information.
PMS50
differenCeS in Patient CharaCteriStiCS and utilization PatternS 
of SuBCutaneouS anti-tnf MediCationS oBSerVed in a large united 
StateS Managed Care PoPulation
Ellis L.1, Meyer R.1, Bolge S.1, Zhou Y.2, Howe A.2
1Janssen Scientific Affairs, LLC, Horsham, PA, USA, 2Comprehensive Health Insights, Louisville, 
KY, USA
Objectives: To evaluate patient characteristics and real-world treatment patterns 
of subcutaneous anti-TNF medications for patients enrolled in Humana’s commer-
cial and Medicare patient populations. MethOds: Adult patients (aged ≥ 18 years) 
with ≥ 2 fills of index biologic (adalimumab (ADA), certolizumab (CTZ); etanercept 
(ETA) or golimumab (GLM)) in the post-index period, and continuous eligibility for ≥ 6 
months pre- and 12 months post-index were identified in health care claims. Patient 
age, gender, RxRisk-V score, biologic use and disease modifying anti-rheumatic 
drug (DMARD) use history in the pre-index period were summarized. Utilization 
measures included monthly biologic dose, refill interval, proportion of adherent fills 
(refilled ± 7 days of expected), and proportion of patients with 100% refill adherence. 
Descriptive statistics (mean, SD, n, %), one-way analysis of variance (continuous 
variables), and chi-squared tests (categorical variables) were employed. Results: 
3,568 ADA, 287 CTZ, 3,625 ETA, and 158 GLM patients were studied. The CTZ and 
GLM groups were significantly younger than all others (p< 0.001). The GLM group 
had a higher proportion with prior biologic use (58.2%) vs. ADA (11.1%), CTZ (34.1%), 
and ETA (4.9%); (p< 0.0001). The GLM group had higher mean Rx Risk-V scores as 
compared to ETA (6.51±3.47 vs. 5.94±3.14, respectively; p< 0.05) and had higher pro-
portions of patients with pre-index DMARD use (71.5%) vs. ADA (57.1%), CTZ (54.4%) 
and ETA (52.1%); (p< 0.001). The proportion of patients with 100% of compliant refills 
was significantly greater in the GLM group (39.9%) than ADA -28.6%; CTZ-21.6%; 
ETA-27.3%; p< 0.001) and was statistically lower in the CTZ group as compared to 
all others (p< 0.05). cOnclusiOns: A number of statistically significant differences 
were identified. Golimumab use was associated with a higher proportion of patients 
achieving 100% refill compliance compared to other subcutaneous anti-TNF medica-
tions. The implications of differences in clinical and demographic characteristics 
and medication adherence on patient outcomes require further exploration.
PMS51
treatMent PerSiStenCe With CoMBination VerSuS MonotheraPy in 
CoMMerCially inSured PatientS With rheuMatoid arthritiS
Shah N.1, Bonafede M.M.2, Chastek B.3, Thomson E.2, Song R.3, Harrison D.J.1
1Amgen, Inc, Thousand Oaks, CA, USA, 2Truven Health Analytics, Cambridge, MA, USA, 
3OptumInsight, Eden Prairie, MN, USA
Objectives: To study 1-year treatment persistence among patients with rheuma-
toid arthritis (RA), initiating biologics (etanercept or adalimumab) with or without 
non-biologic disease modifying anti-rheumatic drugs (NbDMARDs). MethOds: 
Adult (≥ 18 years) patients with RA newly treated with etanercept or adalimumab 
with ≥ 360 days continuous enrolment before and after their first (index) biologic 
claim were identified in the MarketScan® Research Databases (Jan 1, 2010-Dec 31, 
2011) and the Optum Research Database (Jan 1, 2009-Oct 1, 2011). Patients with a 
claim for a biologic in the 360 days pre-index or treated with biologics for conditions 
other than RA were excluded. Monotherapy patients met the following criteria at 
index: 1) Initiated monotherapy; no claim for a NbDMARD 360 days pre- and up to 30 
days post-index or 2) Switched to monotherapy; ≥ 1 claim for a NbDMARD between 
day -360 and -30 (pre-index) and no claims for a NbDMARD between day -29 and 
+30. Combination therapy patients met the following criteria: 1) Initiated combi-
nation therapy; no claims for NbDMARDs from day -360 to -30 and ≥ 1 claim for a 
NbDMARD from day -29 to +30 or 2) Switched to combination therapy; ≥ 1 claim for 
a NbDMARD between day -360 and -30, and another claim for a NbDMARD from day 
-29 to +30. Persistence was defined as the number of days from the index date until 
the earlier of a 45-day gap in therapy or a switch to another biologic. Results: Of 
6,626 patients in the MarketScan and 2,426 patients in the Optum databases, 35.7% 
and 36.9% were on biologic monotherapy respectively. Persistence was similar in 
both databases and higher with combination therapy (Truven/Optum: 45.1%/48.6% 
etanercept, 42.6%/47.0% adalimumab) than with monotherapy (Truven/Optum: 
35.5%/43.1% etanercept, 35.1%/44.0% adalimumab). cOnclusiOns: Combination 
therapy was associated with greater persistence than biologic monotherapy.
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12 times more likely to be NWH compared to those walking at normal speed (Odds 
Ratio [OR]: 12.4 95% Confidence Interval [CI] 6.0 -25.6; p< 0.001), after controlling for 
age, gender, race, education, body mass index (BMI), income, and comorbidities. 
Further, the contribution of comorbidities in the model was significantly (p< 0.001) 
weakened when WS entered the model. cOnclusiOns: Walking speed was an 
independent predictor of NWH status among community dwelling women and 
may be useful in the work setting to identify those at high risk of health related job 
loss. Further evaluation of the longitudinal predictive capability of WS is needed.
PMS58
the aSSeSSMent of Shoulder inStaBility: the deVeloPMent and 
Validation of a QueStionnaire – the oxford Shoulder inStaBility 
SCore (oSiS)
Dawson J.1, Churchman D.2, Fitzpatrick R.1, Carr A.J.3
1University of Oxford, Headington, UK, 2Isis Outcomes, Oxford, UK, 3University of Oxford, Nuffield 
Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, Oxfordshire, 
UK
Objectives: To develop a questionnaire for completion by patients presenting with 
shoulder instability. MethOds: A draft 18 item questionnaire was developed using 
themes identified from interviews with patients (n= 20). The draft questionnaire 
was then tested on further groups of 20 patients attending an outpatient clinic, to 
which they had been referred with instability of the shoulder. Following modifica-
tion resulting from patient feedback, the revised 12 item questionnaire was then 
tested in a prospective study of consecutive patients attending out-patient clinics 
for shoulder instability (n= 98). Patients completed patient-reported and clinical 
assessments pre-intervention (physiotherapy or surgery) and again at 6 months 
following treatment. The questionnaire was evaluated regarding its internal consist-
ency, reproducibility, validity and responsiveness (sensitivity to change). Results: 
The results provide evidence of good measurement properties of the questionnaire: 
Internal consistency - Cronbach’s alpha was 0.91 at the pre-treatment assessment (n 
= 92) and 0.92 at follow-up (n = 64). Reproducibility - In the test-retest sample (n = 
34), the correlation between the total scores for the questionnaire was high (r = 0.97, 
p < 0.0001), coefficient of reliability 5.7. Construct validity - The new questionnaire 
correlated well with the Constant and Rowe clinical scores both before operation 
and at the six-month follow-up. It also agreed significantly with the related parts 
of the SF36, particularly in physical function and pain. Responsiveness – The new 
questionnaire and the Rowe clinical score (but not the Constant) each achieved a 
large standardised effect size (≥ 0.8) that surpassed values obtained on relevant 
SF36 domains. cOnclusiOns: We developed and tested a short patient-reported 
12-item questionnaire (‘score’) which patients have found easy to complete and 
which provides reliable, valid and responsive information as to their perception 
of shoulder instability.
PMS59
CharaCteriStiCS of PatientS With rheuMatoid arthritiS SaMPled 
froM a Patient adVoCaCy organization VerSuS a ConSuMer Panel: 
iMPliCationS for Patient-Centered reSearCh
Bolge S.1, Brown D.2, Goren A.2, Ginsberg S.3
1Janssen Scientific Affairs, LLC, Horsham, PA, USA, 2Kantar Health, New York, NY, USA, 3Creaky 
Joints, Upper Nyack, NY, USA
Objectives: Much information about the disease experience can only be obtained 
directly from patients. However, biases may be introduced to patient-reported 
research depending on the source of the sample. This analysis seeks to identify 
differences in demographic and disease characteristics between samples of patients 
with rheumatoid arthritis (RA) recruited through an advocacy organization and 
a consumer panel. MethOds: Data were collected online from two groups of 
patients through self-administered questionnaires. Patients were recruited through 
the patient advocacy organization CreakyJoints and the Lightspeed Research con-
sumer panel. Patients in both groups were U.S. adults (aged ≥ 18), diagnosed with 
RA, currently treated by a rheumatologist with disease modifying anti-rheumatic 
drugs (DMARDs), and with no history of biologic use but had discussed biolog-
ics with their physician. Results: A total of 243 patients completed the study. Of 
these, 101 were from the advocacy organization and 142 were from the consumer 
panel. Patients from the advocacy organization were younger (mean age, 46 vs. 57) 
and more likely to be female (93% vs. 80%), employed (53% vs. 31%), have a college 
degree (59% vs. 43%), and have commercial insurance (70% vs. 51%) than patients 
from the consumer panel (p< 0.05 for all comparisons). Patients from the advocacy 
organization also began experiencing RA symptoms more recently (mean years 
since symptom development, 10 vs. 15) and were more likely to be diagnosed by a 
rheumatologist (73% vs. 51%), have a caregiver (47% vs. 24%), and be non-adherent 
with medication (61% vs. 42%) than patients from the consumer panel (p< 0.05 for all 
comparisons). cOnclusiOns: Members of patient advocacy organizations and con-
sumer panels can differ demographically and in their disease characteristics. The 
potential impact of these differences on study results should be considered when 
developing a sampling and recruitment plan for patient-centered survey research.
PMS60
Patient-rePorted outCoMeS in SurgiCal PraCtiCe: PreoPeratiVe 
PrediCtorS of Poor outCoMe folloWing PriMary total knee 
arthroPlaSty
Kirkness C.S.1, Ren J.1, Marcus R.L.2, LaStayo P.C.2, Peters C.L.2, Erickson J.3, Greene T.H.4,  
Fritz J.M.2
1University of Illinois, Peoria, IL, USA, 2University of Utah, Salt Lake City, UT, USA, 3University of 
Utah, 4University of Utah, UT
Objectives: Identifying those at highest risk of poor outcomes is critical to popu-
lation health management. The purpose of this study was to identify preoperative 
factors and comorbidities that are associated with those at risk of poor patient-
reported physical function recovery one year following total knee arthroplasty 
(TKA). MethOds: Primary TKA unilateral procedures from a patient-reported total 
However, further methodological research is needed to achieve standardization 
of procedures.
PMS55
eValuating the degree to WhiCh aBility to Pay and health-related 
Quality of life (hrQol) influenCe WillingneSS to Pay (WtP) in 
PSoriaSiS and PSoriatiC arthritiS PatientS
Dierick K.1, Worsfold A.2, Gillis L.2, Rose A.2
1GfK Disease Atlas, Brussels, Belgium, 2GfK Disease Atlas, London, UK
Objectives: The aim of this study was to measure what matters most in WTP for 
a treatment, the patients’ perception of their health status, their ability to pay, or a 
combination of both. MethOds: 395 US patients diagnosed with either psoriasis 
(n= 151) or psoriatic arthritis (n= 247) completed a questionnaire as part of a broader 
survey of treatment of psoriasis/psoriatic arthritis in the US. The questionnaire 
included the EQ-5D-5L instrument and accompanying VAS. Patients were addition-
ally asked to indicate by reference to the EQ-5D VAS scale the amount of money 
per month they would be willing to pay for treatments that would improve their 
health status by 10 points, retain their current health and prevent a decline in 
health status by 10 points. Annual household income information was also reported 
by patients. Patients were split into 3 equal groups based on their VAS. Results: 
Household income was a better predictor of WTP for a treatment; those patients 
with an annual income of less than $25000 were willing to pay the least (p< 0,001), 
whereas patients with an annual household income over $75000 would pay most 
(p< 0,001). Patients within the lowest VAS segment were prepared to pay significantly 
more for an improvement in their health status than patients within the other seg-
ments (p< 0,003). No significant differences were noted between groups to either 
retain health status or avoid health decline. For predicting WTP for an improvement 
in health status, a combination of low yearly income (< $25000) and the EQ-5D VAS 
was the best (sig < 0.001); WTP for a 10 VAS point improvement = $142 + (-$39,9*Low 
Income) + (-$0,7*VAS score). cOnclusiOns: Both ability to pay and health status 
are valid predictors of willingness to pay for a treatment. Yet ability to pay is a better 
overall predictor of willingness to pay than HRQoL.
PMS56
funCtional StatuS and laBor ProduCtiVity With tofaCitiniB in 
PatientS With inadeQuate reSPonSe to non-BiologiCal diSeaSe-
Modifying antirheuMatiC drugS (dMard) VerSuS anti-tuMor 
neCroSiS faCtor drugS (anti-tnf) in ColoMBia
Vargas-Valencia J.J.1, Vargas Zea N.2, Gutierrez-Ardila M.V.2
1Econopharma Consulting S.A. de C.V., Mexico City, Mexico, 2Pfizer S.A.S., Bogotá, Colombia
Objectives: To evaluate the benefits in functional status and labor productivity 
of tofacitinib in patients with inadequate response to a non-biological DMARD vs 
anti-TNF in Colombia. MethOds: The response to treatment was assessed by the 
change from baseline in the Health Assessment Questionnaire-Disability Index 
(HAQ-DI) from baseline and works lost productivity: absenteeism and presentee-
ism (productivity reduction ≥ 50%) due patient’s functional status, as reported by 
Chaparro del Moral R. 2012 and Hazes JM. 2010 who measured absenteeism accord-
ing to functional status regardless of treatment received. Comparison between anti-
TNF and tofacitinib (5mg BID) was done directly to adalimumab (heat-to-heat study) 
and indirectly (Bucher´s indirect comparisons adjusted method) vs other anti-TNF 
available in Colombia (certolizumab, etanercept, golimumab and infliximab) using 
methotrexate as reference therapy. A discrete event model that simulates six cohorts 
of 1,000 patients (each per treatment option) was developed; productivity hours 
lost was projected according to HAQ level (< 0.5; 0.5-0.87; > 0.87), during 52 weeks 
horizon. Variations in HAQ levels (basal and weekly mean chance), absenteeism 
and presenteeism hours were probabilistically generated assuming a normal dis-
tribution. The results obtained with the anti-TNF’s are grouped and weighted given 
their market share as reported in the SISMED by the Health Ministry. Results: 
Improvement in HAQ-DI score at 3, 6, 9 and 12 months from baseline with tofaci-
tinib and anti -TNF were 61.9, 48.7, 65.2 and 53.2%; and, 49.5, 42.7, 57.1 and 47.1%, 
respectively (t-test at 52 weeks, p< 0.001). As result of these reductions, the hours 
of absenteeism/presenteeism losses along the 52-week horizon were obtained, at 
last observation week: 2.72/2.67 and 4.04/7.23 hours with tofacitinib and anti-TNF 
respectively. cOnclusiOns: The superior reduction in HAQ-DI scale at 52 weeks 
obtained with Tofacitinib in patients with inadequate response to a non-biological 
DMARD results in a greater reduction in work lost productivity, presenteeism and 
absenteeism, compared to anti-TNF available in Colombia.
PMS57
Walking SPeed PrediCtS Work StatuS due to health in CoMMunity 
dWelling WoMen: the oSteoarthritiS initiatiVe (oai)
Kirkness C.S., Ren J.
University of Illinois, Peoria, IL, USA
Objectives: Early identification of declining health in working adults with osteo-
arthritis (OA) may allow targeted interventions that prevent health related job loss. 
Usual walking speed(WS) is a predictor of health status in adults ≥ 65 years41and 
may also be a useful simple predictor of work status in younger adults with OA. 
The study purpose was to determine whether WS is an independent predictor 
of work status in women with or at risk for osteoarthritis adjusting for covari-
ates. MethOds: Participants were 2,634 women (23% African American) age 45-79 
years with baseline WS (Self-selected 20 meters [m]) in the OAI study. Logistic 
regression examined WS as a predictor of work status (working versus not working 
due to health [NWH]) for those walking at slow (< 1.10 meters/second[s]), moderate 
(1.1-1.29 m/s) and normal (> 1.3 m/s) speeds, adjusting for demographics and other 
confounders. Results: Of the 2,634 women (mean age 60.0, Standard Deviation 
[SD] 9.1, years), 57.9% (1,533) were working, 36.0% (952) were not working for other 
reasons and 5.6% (149) were NWH. WS was significantly faster in those working 
compared to those NWH, (mean speed 1.33 m/s vs. 1.08 m/s; p< 0.001). Compared to 
women with normal WS (> 1.3 m/s), those considered slow walkers (WS < 1.10) were 
